Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
ROCO:4157'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.04 Max: 0.1
Current: 0.01
During the past 13 years, the highest Debt-to-Equity Ratio of TaiGen Biopharmaceuticals Holdings was 0.10. The lowest was 0.00. And the median was 0.04.
ROCO:4157's Debt-to-Equity is ranked better than 99.9% of 964
companies
in the Biotechnology industry
Industry Median: 0.155
vs ROCO:4157: 0.01
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
TaiGen Biopharmaceuticals Holdings Debt-to-Equity Related Terms
TaiGen Biopharmaceuticals Holdings Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4157 vs VRTX, REGN, MRNA: Debt-to-Equity Comparison
For the Biotechnology subindustry, TaiGen Biopharmaceuticals Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TaiGen Biopharmaceuticals Holdings Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TaiGen Biopharmaceuticals Holdings's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where TaiGen Biopharmaceuticals Holdings's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TaiGen Biopharmaceuticals Holdings (ROCO:4157) has a Debt-to-Equity of 0.01 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on TaiGen Biopharmaceuticals Holdings and its competitors. This is 75% below median its historical median of 0.04. According to the industry distribution chart, TaiGen Biopharmaceuticals Holdings ranks #1 out of 964 companies in the Biotechnology industry, placing it in the top 0.099999999999994%.
Is TaiGen Biopharmaceuticals Holdings' Debt-to-Equity too high?
TaiGen Biopharmaceuticals Holdings' current Debt-to-Equity of 0.01 is 75% below median its 10-year median of 0.04. The Biotechnology industry median Debt-to-Equity is 0.16. TaiGen Biopharmaceuticals Holdings' value of 0.01 is 93.5% below this industry median. Based on the distribution chart, TaiGen Biopharmaceuticals Holdings ranks #1 out of 964 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, TaiGen Biopharmaceuticals Holdings has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does TaiGen Biopharmaceuticals Holdings' Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, TaiGen Biopharmaceuticals Holdings ranks #1 out of 964 companies for Debt-to-Equity. This places TaiGen Biopharmaceuticals Holdings in the top 0% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.16. TaiGen Biopharmaceuticals Holdings' value of 0.01 is 93.5% below this benchmark. While the company's 10-year median is 0.04 vs. the industry median of 0.16, TaiGen Biopharmaceuticals Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 964 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TaiGen Biopharmaceuticals Holdings's current Debt-to-Equity of 0.01 is 93.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on TaiGen Biopharmaceuticals Holdings and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TaiGen Biopharmaceuticals Holdings's current Debt-to-Equity is 0.01, which is 75% below median its own 10-year median of 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TaiGen Biopharmaceuticals Holdings stock overvalued right now?
Based on GuruFocus' analysis, TaiGen Biopharmaceuticals Holdings (ROCO:4157) is currently considered Possible Value Trap. The stock's GF Value™ is NT$28.96, compared to a current price of NT$9.06 — trading 68.7% below its estimated fair value. The current Debt-to-Equity is 0.01, which is 75% below median its 10-year median of 0.04 and 93.5% below the Biotechnology industry median of 0.16. TaiGen Biopharmaceuticals Holdings' overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For TaiGen Biopharmaceuticals Holdings (ROCO:4157), the current Debt-to-Equity is 0.01 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TaiGen Biopharmaceuticals Holdings (ROCO:4157) Overvalued in 2026?
Based on GuruFocus' analysis, TaiGen Biopharmaceuticals Holdings stock appears to be undervalued.
The current stock price of NT$9.06 is trading 68.7% below its estimated GF Value™ of NT$28.96.
GuruFocus considers TaiGen Biopharmaceuticals Holdings to be Possible Value Trap.
Key valuation signals for ROCO:4157:
Debt-to-Equity: 0.01 (75% below median its 10-year median of 0.04)
GF Value™: NT$28.96 vs. price of NT$9.06 (68.7% below fair value)
Industry Position: 93.5% below the Biotechnology median (#1 of 964)
No single metric tells the full story. See the ROCO:4157 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TaiGen Biopharmaceuticals Holdings Ltd is mainly engaged in the research and development of new drugs, including the selection of drug candidates, pre-IND trials and clinical trials. Its operating segment includes development, research and sales of new drugs, and other. The majority of the revenue is generated from development, research and sales of new drugs.
62GF Score
Get the complete analysis for ROCO:4157
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4157 has been successfully added to your 
